Elonva

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

korifolitropin alfa

Available from:

N.V. Organon

ATC code:

G03GA09

INN (International Name):

corifollitropin alfa

Therapeutic group:

Spolni hormoni in zdravila genitalni sistem,

Therapeutic area:

Reproductive Techniques, Assisted; Ovulation Induction; Investigative Techniques

Therapeutic indications:

Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin (hCG).

Product summary:

Revision: 23

Authorization status:

Pooblaščeni

Authorization date:

2010-01-25

Patient Information leaflet

                                22
Shranjujte v hladilniku. Ne zamrzujte.
Shranjevanje doma
Na voljo sta dve možnosti:
1. Shranjujte v hladilniku. Ne zamrzujte.
2. Shranjujte pri temperaturi do 25

C za obdobje največ 1 meseca.
Injekcijsko brizgo shranjujte v zunanji ovojnini za zagotovitev
zaščite pred svetlobo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
N.V. Organon
Kloosterstraat 6
5349 AB Oss
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/09/609/001
13.
ŠTEVILKA SERIJE
_ _
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI

17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
23
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
NALEPKA NA NAPOLNJENI INJEKCIJSKI BRIZGI
1.
IME ZDRAVILA IN POT(I) UPORABE
Elonva 100 mikrogramov injekcija
korifolitropin alfa
s.c.
2.
POSTOPEK UPORABE
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
0,5 ml
6.
DRUGI PODATKI
24
PODATKI NA ZUNANJI OVOJNINI
ŠKATLA
1.
IME ZDRAVILA
Elonva 150 mikrogramov raztopina za injiciranje
korifolitropin alfa
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena napolnjena injekcijska brizga vsebuje 150 mikrogramov
korifolitropina alfa v 0,5 ml raztopine za
injiciranje.
3.
SEZNAM POMOŽNIH SNOVI
Pomožne snovi: natrijev citrat, saharoza, polisorbat 20, metionin,
natrijev hidroksid (za uravnavanje
pH), klorovodikova kislina (za uravnavanje pH), voda za injekcije
4.
FARMACEVTSKA OBLIKA IN VSEBINA
raztopina za injiciranje
1 napolnjena injekcijska brizga z avtomatskim varnostnim sistemom (za
preprečevanje poškodb z iglo)
in sterilno injekcijsko iglo. 0,5 ml
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
_ _
Samo za enkratno u
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Elonva 100 mikrogramov raztopina za injiciranje
Elonva 150 mikrogramov raztopina za injiciranje
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Elonva 100 mikrogramov raztopina za injiciranje
Ena napolnjena injekcijska brizga vsebuje 100 mikrogramov
korifolitropina alfa* v 0,5 ml raztopine
za injiciranje.
Elonva 150 mikrogramov raztopina za injiciranje
Ena napolnjena injekcijska brizga vsebuje 150 mikrogramov
korifolitropina alfa* v 0,5 ml raztopine
za injiciranje.
*Korifolitropin alfa je glikoprotein, izdelan v ovarijskih celicah
kitajskega hrčka (CHO) z uporabo
tehnologije rekombinantne DNA.
Pomožna(e) snov(i) z znanim učinkom:
To zdravilo vsebuje manj kot 1 mmol natrija (23 mg) na injekcijo, kar
v bistvu pomeni 'brez natrija'.
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
raztopina za injiciranje (injekcija)
bistra in brezbarvna vodna raztopina
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Elonva je indicirano za nadzorovano stimulacijo jajčnikov
(COS) v kombinaciji z uporabo
antagonista gonadotropin sproščujočega hormona (GnRH) za razvoj
več foliklov pri ženskah v
programu asistirane reprodukcije (ART).
Zdravilo Elonva je indicirano za zdravljenje mladostnikov moškega
spola (14 let ali več) s
hipogonadotropnim hipogonadizmom, v kombinaciji s humanim horionskim
gonadotropinom (hCG).
4.2
ODMERJANJE IN NAČIN UPORABE
Zdravljenje z zdravilom Elonva za COS je treba uvesti pod nadzorom
zdravnika, ki je izkušen v
zdravljenju težav s plodnostjo.
Zdravljenje z zdravilom Elonva za hipogonadotropni hipogonadizem je
treba uvesti in mora biti pod
nadzorom zdravnika, ki je izkušen v zdravljenju hipogonadotropnega
hipogonadizma.
Odmerjanje
Za zdravljenje žensk v rodni dobi se odmerek zdravila Elonva določi
glede na telesno maso in starost.
_-_
_ _
Za ženske, ki tehtajo 60 kilogramov ali manj in so stare 36 let ali
manj, je priporočljiv enkraten
odmerek 100 mikrogramov.
3
_-_
_ _
Enkraten odmerek 150 mikrogr
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 05-04-2023
Public Assessment Report Public Assessment Report Bulgarian 05-07-2022
Patient Information leaflet Patient Information leaflet Spanish 05-04-2023
Public Assessment Report Public Assessment Report Spanish 05-07-2022
Patient Information leaflet Patient Information leaflet Czech 05-04-2023
Public Assessment Report Public Assessment Report Czech 05-07-2022
Patient Information leaflet Patient Information leaflet Danish 05-04-2023
Public Assessment Report Public Assessment Report Danish 05-07-2022
Patient Information leaflet Patient Information leaflet German 05-04-2023
Public Assessment Report Public Assessment Report German 05-07-2022
Patient Information leaflet Patient Information leaflet Estonian 05-04-2023
Public Assessment Report Public Assessment Report Estonian 05-07-2022
Patient Information leaflet Patient Information leaflet Greek 05-04-2023
Public Assessment Report Public Assessment Report Greek 05-07-2022
Patient Information leaflet Patient Information leaflet English 05-04-2023
Public Assessment Report Public Assessment Report English 05-07-2022
Patient Information leaflet Patient Information leaflet French 05-04-2023
Public Assessment Report Public Assessment Report French 05-07-2022
Patient Information leaflet Patient Information leaflet Italian 05-04-2023
Public Assessment Report Public Assessment Report Italian 05-07-2022
Patient Information leaflet Patient Information leaflet Latvian 05-04-2023
Public Assessment Report Public Assessment Report Latvian 05-07-2022
Patient Information leaflet Patient Information leaflet Lithuanian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 05-04-2023
Public Assessment Report Public Assessment Report Lithuanian 05-07-2022
Patient Information leaflet Patient Information leaflet Hungarian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 05-04-2023
Public Assessment Report Public Assessment Report Hungarian 05-07-2022
Patient Information leaflet Patient Information leaflet Maltese 05-04-2023
Public Assessment Report Public Assessment Report Maltese 05-07-2022
Patient Information leaflet Patient Information leaflet Dutch 05-04-2023
Public Assessment Report Public Assessment Report Dutch 05-07-2022
Patient Information leaflet Patient Information leaflet Polish 05-04-2023
Public Assessment Report Public Assessment Report Polish 05-07-2022
Patient Information leaflet Patient Information leaflet Portuguese 05-04-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 05-04-2023
Public Assessment Report Public Assessment Report Portuguese 05-07-2022
Patient Information leaflet Patient Information leaflet Romanian 05-04-2023
Public Assessment Report Public Assessment Report Romanian 05-07-2022
Patient Information leaflet Patient Information leaflet Slovak 05-04-2023
Public Assessment Report Public Assessment Report Slovak 05-07-2022
Patient Information leaflet Patient Information leaflet Finnish 05-04-2023
Public Assessment Report Public Assessment Report Finnish 05-07-2022
Patient Information leaflet Patient Information leaflet Swedish 05-04-2023
Public Assessment Report Public Assessment Report Swedish 05-07-2022
Patient Information leaflet Patient Information leaflet Norwegian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 05-04-2023
Patient Information leaflet Patient Information leaflet Icelandic 05-04-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 05-04-2023
Patient Information leaflet Patient Information leaflet Croatian 05-04-2023
Public Assessment Report Public Assessment Report Croatian 05-07-2022

Search alerts related to this product

View documents history